Inovio Pharmaceuticals (NASDAQ:INO) Announces Quarterly Earnings Results

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.18, Zacks reports. The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.03 million.

Inovio Pharmaceuticals Price Performance

INO traded down $0.13 on Wednesday, reaching $1.97. 376,567 shares of the stock were exchanged, compared to its average volume of 827,769. The company’s 50-day moving average price is $2.05 and its 200 day moving average price is $3.77. The firm has a market capitalization of $51.47 million, a PE ratio of -0.94 and a beta of 0.92. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on INO shares. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, Royal Bank of Canada lowered their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals currently has an average rating of “Hold” and an average target price of $12.20.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.